Abstract
Purpose To assess the safety and potential toxicity of proton beam radiation in the treatment of subfoveal choroidal neovascular membrane (CNVM) due to age-related manner degeneration (ARMD) in a prospective, non-randomised study.
Methods Forty-eight eyes of 46 consecutive patients with subfoveal CNVM due to ARMD, not amenable to laser photocoagulation, were treated prospectively with a single proton beam exposure. Two dose regimens were evaluated: 8 CGE (Cobalt Gray Equivalent) and 14 CGE. Patients were followed for an average of 22.1 months after proton beam treatment.
Results At the 12 month follow-up, 44% of eyes in the 8 CGE group and 75% of the eyes in the 14 CGE group had stabilised or improved visual acuity. Complex size in the 8 CGE group as measured on standard fluorescein angiography (FA), decreased or had no change initially but showed less effect over time, while the eyes treated with 14 CGE maintained decreased leakage over the follow-up period of 12 months. However, 11 eyes in the 14 CGE group experienced radiation retinopathy, with the onset between 3 and 30 months. Seven of these 11 eyes have demonstrated some visual loss but only 1 eye developed severe visual loss at 15 months after proton treatment.
Conclusions To date, 14 CGE has suggested a favourable influence on visual function and growth inhibition of CNVM. Proton beam irradiation appears to inhibit CNVM growth. The 14 CGE dose regimen appears to have a longer effect of CNVM growth than does 8 CGE, with overall stabilisation of visual function and growth inhibition. Radiation retinopathy has developed over time, but severe visual loss has been limited. On the basis of the incidence of radiation retinopathy, adjustments in the total radiation dosage and/ or fractionation of the dosage should be considered.
Similar content being viewed by others
Article PDF
References
Ferris FL, Fine SL, Hyman L . Age-related macular de't, eueïatou and buduess due to ueolascuaï macu'opathy. Arch Ophthalmol 1984;102:1640–2.
American Academy of Ophthalmology. Age-related macular degeneration: preferred practice pattern. San Francisco: American Academy of Ophthalmology, 1998.
Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol 1986;104:694–701.
Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. Br J Ophthalmol 1982;66:745–53.
Freund KB, Yannuzzi LA, Sorenson JA . Age-related macular degeneration and choroidal neovascularisation. Am J Ophthalmol 1993;115:786–91.
Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994;112:480–8.
Chakravarthy U, Houston RF, Archer DB . Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993;77:265–73.
Bergink GJ, Deutman AF, van den Broek JF, et al. Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 1994;232:591–8.
Bergink GJ, Deutman AF, van den Broek JE, et al. Radiation therapy for age-related subfoveal choroidal neovascular membranes: a pilot study. Doc Ophthalmol 1995;90:67–74.
Yonemoto LT, Slater JD, Friedrichsen EJ, et al. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys 1996;36:867–71.
Macular Photocoagulation Study Group. MPS manual of procedures. Springfield: National Information Service, Accession no. PB91-159368, 1991:8:1–12.
Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study. Arch OphthalmoI 1991;109:1242–57.
Chan CK, Kempin SJ, Noble SK, Palmer GA . The treatment of choroidal neovascular membranes by alpha interferon: an efficacy and toxicity study. Ophthalmology 1994;101:289–300.
Fung WE . Interferon alpha 2a for treatment of age-related macular degeneration [letter]. Am J Ophthalmol 1991;112:349–50.
Gillies MC, Sarks JP, Beaumont PE, et al. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b [see comments]. Br J Ophthalmol 1993;77:759–65.
Aiello LP . Vascular endothelial growth factor and the eye: past, present and future [editorial; comment]. Arch Ophthalmol 1996;114:1252–4.
Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538–44.
Finger PT, Berson A, Sherr D, et al. Radiation therapy for subretinal neovascularization. Ophthalmology 1996;103:878–89.
Slater JM, Archambeau JO, Miller DW, et al. The proton treatment center at Lorna Linda University Medical Center: rationale for and description of its development. Int J Radiat Oncol Biol Phys 1992;22:383–9.
Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented in part at the annual meeting of the American Academy of Ophthalmology, October 1996; the Vitreous Society Meeting, December 1996; the International Age-Related Macular Degeneration Meeting, September 1997; and the Association for Research in Vision and Ophthalmology annual meeting, May 1997 and April 1998
Financial support: Inland Vision Foundation, Kaiser Permanente Academic Research, The Hearst Foundation, Clayton Foundation, Foundation for Research to Prevent Blindness
Rights and permissions
About this article
Cite this article
Flaxel, C., Friedrichsen, E., Smith, J. et al. Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye 14, 155–164 (2000). https://doi.org/10.1038/eye.2000.46
Issue Date:
DOI: https://doi.org/10.1038/eye.2000.46
Keywords
This article is cited by
-
One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study
Ophthalmology and Therapy (2022)
-
Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long-term results
Eye (2020)
-
The Effectiveness and Safety of Proton Radiation Therapy for Indications of the Eye
Strahlentherapie und Onkologie (2009)
-
Radiotherapy for choroidal neovascularisation of age-related macular degeneration: A fresh perspective
Eye (2000)